{"name":"CAGE Bio Inc.","slug":"cage-bio-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":6,"colorKey":"oncology","drugs":[{"name":"Drug: CGB-600 gel, experimental drug","genericName":"Drug: CGB-600 gel, experimental drug","slug":"drug-cgb-600-gel-experimental-drug","indication":"Other","status":"phase_1"},{"name":"CGB-500 with 0.5% tofacitinib","genericName":"CGB-500 with 0.5% tofacitinib","slug":"cgb-500-with-0-5-tofacitinib","indication":"Other","status":"phase_2"},{"name":"CGB-S-100","genericName":"CGB-S-100","slug":"cgb-s-100","indication":"Other","status":"phase_1"},{"name":"CGB-400","genericName":"CGB-400","slug":"cgb-400","indication":"Other","status":"phase_2"},{"name":"CGB-400 Topical Gel","genericName":"CGB-400 Topical Gel","slug":"cgb-400-topical-gel","indication":"Other","status":"phase_2"},{"name":"Ruxolitinib 1.5% Cream QD","genericName":"Ruxolitinib 1.5% Cream QD","slug":"ruxolitinib-1-5-cream-qd","indication":"Other","status":"phase_2"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"CGB-500 Ointment with 1% tofacitinib","genericName":"CGB-500 Ointment with 1% tofacitinib","slug":"cgb-500-ointment-with-1-tofacitinib","indication":"Rheumatoid arthritis","status":"phase_2"}]}],"pipeline":[{"name":"Drug: CGB-600 gel, experimental drug","genericName":"Drug: CGB-600 gel, experimental drug","slug":"drug-cgb-600-gel-experimental-drug","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"CGB-500 with 0.5% tofacitinib","genericName":"CGB-500 with 0.5% tofacitinib","slug":"cgb-500-with-0-5-tofacitinib","phase":"phase_2","mechanism":"Combination therapy incorporating tofacitinib, a JAK inhibitor, with CGB-500, whose mechanism remains undisclosed.","indications":[],"catalyst":""},{"name":"CGB-S-100","genericName":"CGB-S-100","slug":"cgb-s-100","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"CGB-400","genericName":"CGB-400","slug":"cgb-400","phase":"phase_2","mechanism":"CGB-400 is designed to target and inhibit a specific pathway involved in disease progression, though the exact mechanism is not publicly disclosed.","indications":[],"catalyst":""},{"name":"CGB-400 Topical Gel","genericName":"CGB-400 Topical Gel","slug":"cgb-400-topical-gel","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"CGB-500 Ointment with 1% tofacitinib","genericName":"CGB-500 Ointment with 1% tofacitinib","slug":"cgb-500-ointment-with-1-tofacitinib","phase":"phase_2","mechanism":"Tofacitinib is a Janus kinase (JAK) inhibitor that suppresses the activity of JAK enzymes, which play a key role in the signaling of cytokines involved in inflammation.","indications":["Rheumatoid arthritis"],"catalyst":""},{"name":"Ruxolitinib 1.5% Cream QD","genericName":"Ruxolitinib 1.5% Cream QD","slug":"ruxolitinib-1-5-cream-qd","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMihAJBVV95cUxOVllTWE5vUlY0S1p3YzJDbjd3Q3NGS3R1WmNHdEtUd2pBeFhHcm1ZeWkzdk9LdFZlV1FjemhlT3lUcDJfS0J3dzZfRGNlZzliSThiM2o3TzNhQXE2VG5RTkp3eHlDX0hZSGVGb0R2Z21YMHNUTzRNQ1E0NW81UGlzLXlKWTExazlhTkFlUnJEbERrM1VZNXBlTkhMLWFlYWNYZkVLQ3dnVkpyZkJKY0ZuZkpfdUVTZEdqWkF2ZDhxa2M3eGNIYkRHaVhibUFXVzRqZW1wOGRjZzhrNVh1U1JHS2dDVmF1MUh4QVFCNDU4Z3YycGdjVkhybmhCcmJzWTlfTTZ4bw?oc=5","date":"2025-10-23","type":"trial","source":"PR Newswire","summary":"CAGE Bio Announces Start of Double-Blind Vehicle-Controlled Clinical Trial of Novel Topical DNA Aptamer Therapy CGB-600 for Vitiligo Treatment - PR Newswire","headline":"CAGE Bio Announces Start of Double-Blind Vehicle-Controlled Clinical Trial of Novel Topical DNA Aptamer Therapy CGB-600 ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxQUVJfRmo4NWllVWRaeDZ5MVRNcnZlSS1HVDIxM1lxS2Z6YXJqZGZPZURHVnVDZTV5bnptVVZHN1FDc0hfbHFPSGlSSDJ3VGkzUVF3RjJFdjVBcFlDVUd5RE5EcVZkNFd5amNraThrWWZOclFiQ0NXaWhwMC1mYlBYV3ZyN1R1RWZza1JiWkZMSmEtcUdPUE9TYlpoNzAzOEVmcDNzVF9xT0xLblhxS0d1RWh3dHZ2VkFuLTd4aXo0UU1KdEhxbE9Ccg?oc=5","date":"2025-09-04","type":"trial","source":"PR Newswire","summary":"CAGE Bio Reports Strong Results from its Phase 2b Atopic Dermatitis Trial - PR Newswire","headline":"CAGE Bio Reports Strong Results from its Phase 2b Atopic Dermatitis Trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-AFBVV95cUxNVWp3TnZ5bDJjUXNaeGY5d0RqMlZ4dnhYelVFWXJPSEVWQ05JTWNBQmJPdDBsT0FYVGlLZEdsSTZCVXhxT3BETXlEQmtQWnpsMk9qSENXWXF3XzZiN0R4dXNYYlFBcXphLVRlQUlLMnFIM05nRTFUVmhicjdNWmFoY09iSWs0RWFVbXNpQ2VaeWNrZXhSNUYxOXFLQXdvdE01cWRKTV9zdUp3cy1kejkwS2R2NVpzbkFZUUlHU0F2b05WTGJ3dTdGSFhJaGZGTloyV2p4T2lsdWRsbmJxMUVVTjZKVnVyd0RmaGxyaVBhMmFTYUZrZ05DMQ?oc=5","date":"2025-08-27","type":"deal","source":"PR Newswire","summary":"CAGE Bio Announces Collaboration to Advance First-in-Class Treatments for Cutaneous Graft versus Host Disease - PR Newswire","headline":"CAGE Bio Announces Collaboration to Advance First-in-Class Treatments for Cutaneous Graft versus Host Disease","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxOUGQ0c2NxSG9ZM3FNcFZUYWFTTkJZeElxUHlPaE9lejZvaHdpV1BkQ1Q3a1ZsX2lUd3RmM2lKRHpCd3podjFGb3pnZDRJQ3hYa2dDd3lwSFk2Ung0OWYxcWZ6elltTk9SLVRTRWEzTzg4ZWw5ZktBS1NnTzFMWVpWSEdia1BnRHZBUDAyVU1HOHZiZFNLRTVVVkY0YUwxblhyZVN0YQ?oc=5","date":"2025-07-15","type":"pipeline","source":"Dallas Innovates","summary":"CAGE Bio Relocates Fort Worth Office to BioLabs at Pegasus Park in Dallas - Dallas Innovates","headline":"CAGE Bio Relocates Fort Worth Office to BioLabs at Pegasus Park in Dallas","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1gFBVV95cUxQVjZ3ME0tMG5ialo2LU5NSHhMeE9wdFlkTmRiNFhRTTlUS1ZMdTZvYkpQZThGWkt3UzRzLXdWWGJ4ZUtiX1ZIUzBGc2R0RGtOaUNDZ1VYMkFOM0hUQnZUc0NkcUNpLXdSN1JuNFNvNXMwbEtxMXBWdWEzcEtiUWVKZ3B4SFoxZmphcVBpUFJlMW90ODRISVJFYVU1dDhUaVhmNFBHbmRfc0VFcmJ3bDRWcjBaSk5tMzQ0SnUzbDR6RDhIbHp4QnYxN1pIV3JCRDJOVXJXVGZR?oc=5","date":"2025-06-30","type":"pipeline","source":"D Magazine","summary":"Healthcare Briefs: EY Names Healthcare Entrepreneur of the Year and Resource Center Launches Healthcare Team - D Magazine","headline":"Healthcare Briefs: EY Names Healthcare Entrepreneur of the Year and Resource Center Launches Healthcare Team","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxQcU1vNDUxOW14bGhNUUk2a0NRSmVqYnk1dlVmZEdaQnRYc1lEem5sN3hJZHNpdGNRRG43T3BPd3JtbWprVld3Q1Ffa1FEZk9zUTVfRVNSMWVNVExxYm1HQUZ3eUk4b0ZVOS16Y1NZY0trTFFjcmJSMkJhblBoZ3J3N1V4ejY1Y1I4ejhNdllwLW81QzNxQXpHdDlVbm9JV3BfUHdqTVpRTQ?oc=5","date":"2025-06-27","type":"pipeline","source":"The Business Journals","summary":"Pegasus Park lands Silicon Valley startup focused on skin treatments - The Business Journals","headline":"Pegasus Park lands Silicon Valley startup focused on skin treatments","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxNVXNKYjZjMk1aZVlKMVl3ZDdoUEdTWUUtd1FTNGZnYkNMZndfdDhnbW4taHhqeUE2R2ZoQnhURG5BZ0pWMnJCZ1JUaFN6YWdOdjNZOFh4cG5XVEhQUDE1cjdkM1dmckRGQW9SaTlLeUx6RDQyUkVzNkExSGpBN09ENDdSU21ZcFRfRWpUTVBFRkV3UQ?oc=5","date":"2025-03-13","type":"pipeline","source":"statnews.com","summary":"Biotech raising $35 million to take a second stab at cancer drug from Bert Vogelstein’s lab - statnews.com","headline":"Biotech raising $35 million to take a second stab at cancer drug from Bert Vogelstein’s lab","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxONjRJRnVtTmVMZ0lyYlhaY1g5NXQtQ0p1enVoZ2dnYmRFek8wN3B6VU91azl5M3Z5bmFoakwwMUNrUHB4RE1Gd1BZQTByT3EzdXpydW5SLU1LQXAxUFdQUlYtNmdoWEFIUThZU1h6WkFYdU85WmY1SC1hT2ExNUpRYk9yRXNBY3Zpb19zSXdLX0Q1MnNaMXc?oc=5","date":"2024-10-30","type":"pipeline","source":"BioPharma Dive","summary":"A new biotech, built around protein design, springs from David Baker’s lab - BioPharma Dive","headline":"A new biotech, built around protein design, springs from David Baker’s lab","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0AJBVV95cUxOTzd0VHZtSWZSWldNOTU5eGNfM0JDczRScHVuZElzUFBVakpHcUdKaUV2MkZOQmhFMVgyQjNRd3d4cFdTUDFEQl9ZLXo2ZmpwN1pJSS0wcFJqRHpZVWR5N281QlZFWndraU1uSVVpWjNqUG9RVnBJamVxN1NVREhNM0MzYkdlM0RCeEp3TzdsUE9mdy1XZ1U3RmxIeVNMSExQUjhWOUdTX3lkRm1KN0NqN09PVjhWZ3FuSWFwbTdnWjhGeHlPTXIzczUxTnJ2V2x5RnRjZmZzcFJfa3FGcFRCOHRkQUZiR1V1OHBYSVJ3MzNVb3lYSWhPVUNlUE1yWmpRMmJrZ0NlTF9sazdDSmpOWlhFTzFjMnl6SjdpcjBzbVpDdDZyeE5DZUVXaS1tQnZncmsyWFNMVDRJRjctclBFaU9qa1duNFFDSkxpQTY4Z28?oc=5","date":"2024-01-15","type":"pipeline","source":"PR Newswire","summary":"Lyme Disease Treatment Market is Expected to Showcase Significant Growth by 2032, Assesses DelveInsight | Key Companies - Pfizer, ModernaTX, Tarsus Pharmaceuticals, Valneva, Cortene - PR Newswire","headline":"Lyme Disease Treatment Market is Expected to Showcase Significant Growth by 2032, Assesses DelveInsight | Key Companies ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxOLWtIX0l5QlQ5Wkx4dEFsdzFmZjB5Ri04NlV5elNRQVVJdjRsR3ctN0xUNjdzNWp6ZEVpUm1Xd1FHT2k0MzUtdC13b19YMDRKWXV5VzU4YWtMZGxiSGNLSFJrYXN3b1lzRlFmMDJncUNvdXp1dEdYYkM5OHdwT2xxeE9zVDJCZW9KYU56d0M4RVJwOEpwbHU1MTRDcThkM3F6U1hvQg?oc=5","date":"2021-11-18","type":"trial","source":"BioWorld News","summary":"Mereo heads into phase III with drug for brittle bone disease - BioWorld News","headline":"Mereo heads into phase III with drug for brittle bone disease","sentiment":"neutral"}],"patents":[],"drugCount":7,"phaseCounts":{"phase_1":2,"phase_2":5},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}